Drug Induced Liver Injury Conference XIV
Serious drug-induced liver injury is a major problem for both drug development and clinical care. Liver injury defined as serious includes that causing disability from work, need for hospitalization, secondarily impaired renal or brain function, acute liver failure, death, or liver transplantation. Much time, effort, and cost is expended on clinical trials to avoid possibly dangerous new drugs. We seek new understanding to identify especially susceptible rare patients before their liver injury becomes irreversible. We need to solve hepatotoxicity problems that affect pharmaceutical industry protocols, government regulatory bodies, academic consultants to both, and all physicians using drugs to treat patients in the US and worldwide.
This meeting was held March 19-20, 2014
Predicting Serious Drug-Induced Liver Injury in Patients
Who Gets It? Who Doesn't? Why?
The program is co-sponsored by the Food and Drug Administration/Center for Drug Evaluation and Research (FDA/CDER), the Critical Path Institute (C-Path), and the Pharmaceutical Research and Manufacturers of America (PhRMA). The program is endorsed by the National Institutes of Health (NIH) drug-induced liver injury network (DILIN), and the American Association for the Study of Liver Diseases (AASLD).
John R. Senior, MD, Paul Watkins, MD and Lana Pauls, MPH
Speakers: (Note: Click on the Talk Title to view slides)
Bios and Presentation Links (pdf)